Affimed Announces Appointment of Angus Smith as Chief Financial Officer
June 11 2020 - 6:30AM
Mr. Smith brings broad financial
management and US capital markets expertise
Heidelberg, Germany, June 11,
2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer, today announced the appointment of
Angus Smith as Chief Financial Officer, completing Affimed’s
leadership team. Mr. Smith will begin his employment on July 13,
2020 and will be based out of Affimed’s New York office.
Mr. Smith has broad biopharmaceutical industry
experience including financial strategy, capital markets, business
development and operations. He joins Affimed from Rockwell Medical,
Inc., where he served as Chief Financial Officer.
“We are pleased to welcome Mr. Smith who adds
extensive US capital markets expertise,” said Dr. Adi Hoess,
Affimed’s CEO. “His biopharmaceutical industry experience and track
record of financial execution for life sciences companies will help
ensure that Affimed is well positioned as we enter the next stage
of rapid growth.”
“This is an exciting time to join Affimed and I
look forward to contributing to the success of the company as it
progresses its clinical and pre-clinical programs,” said Mr.
Smith. “I look forward to applying my experience in
late-stage pharmaceuticals in order to evolve the company and
accelerate our ability to bring much needed therapeutics to cancer
patients who deserve more options.”
Prior to Rockwell, a biopharmaceutical
company focused on developing and commercializing therapies for
anemia, Mr. Smith served as Senior Vice President, Chief Business
Officer and Principal Financial Officer at Pernix
Therapeutics, a specialty pharmaceutical company focused on the
acquisition, development and commercialization of prescription
drugs.
Mr. Smith began his career in healthcare
investment banking, having served as a Director in
the Healthcare Investment Banking Group at Cantor
Fitzgerald. During his nearly decade-long investment banking
tenure, Mr. Smith focused on providing strategic and financial
advice to life sciences and healthcare companies. He has
worked on a substantial number of transactions across the
healthcare sector with an aggregate transaction value of more than
$15 billion.
Mr. Smith holds a B.A. in Mathematical Economics
from Colgate University.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The company is developing single and
combination therapies to treat hematologic and solid tumors. The
company is currently enrolling patients into a
registration-directed study of AFM13 for CD30-positive
relapsed/refractory peripheral T cell lymphoma and into a Phase
1/2a dose escalation/expansion study of AFM24 for the treatment of
advanced EGFR-expressing solid tumors. For more information, please
visit www.affimed.com
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements appear in a number of
places throughout this release and include statements regarding our
intentions, beliefs, projections, outlook, analyses and current
expectations concerning, among other things, the value of our ROCK®
platform, our ongoing and planned preclinical development and
clinical trials, our collaborations and development of our products
in combination with other therapies, the timing of and our ability
to make regulatory filings and obtain and maintain regulatory
approvals for our product candidates, our intellectual property
position, our collaboration activities, our ability to develop
commercial functions, clinical trial data, our results of
operations, cash needs, financial condition, liquidity, prospects,
future transactions, growth and strategies, the industry in which
we operate, the trends that may affect the industry or us and the
risks, uncertainties and other factors described under the heading
“Risk Factors” in Affimed’s filings with the Securities and
Exchange Commission. Given these risks, uncertainties and other
factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future.
Affimed Investor and Media
Contacts
Alex FudukidisHead of Investor RelationsTel.:
(917) 436-8102E-Mail: a.fudukidis@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024